A patent on a peptide found under a research-only permit

Approvals and obligations:

1. The collection permit. It expressly bars commercial exploitation and third-party transfer. Filing on, or transferring the clone to, the startup would breach it. Written amendment or a fresh agreement from the Chief Wildlife Warden (and the Forest Department) is required first.
2. Biological Diversity Act 2002 framework. Access by Indian researchers is comparatively open, but commercial utilisation, and especially transfer of the results of research to a foreigner or foreign company, requires prior approval of the National Biodiversity Authority (Sections 19–20 and the associated regulations), with intimation to the State Biodiversity Board and a benefit-sharing arrangement. The foreign collaborator's role makes NBA approval unavoidable.
3. Nagoya Protocol / ABS. If any material leaves the country, prior informed consent and mutually agreed terms with benefit sharing must be documented, and the ABS Clearing-House record kept with the strain.
4. Institutional and contractual. University IP policy, the student's enrolment terms, the collaborator's MTA (silent on IP is not the same as permissive), and the sponsor's agreement must all be reconciled before filing.

Effect of the preprint: the preprint discloses the full sequence, the producing clone and the activity data to the world. That is a novelty-destroying public disclosure for claims to the peptide per se, the isolated polynucleotide and the strain. India has no general 12-month grace period, and the narrow exceptions in the Patents Act (e.g. disclosure at a recognised exhibition or by a learned society within 12 months) do not comfortably cover a self-posted preprint. Realistic remaining options are a novel analogue with improved properties, a new manufacturing process, a pharmaceutical composition or formulation, a new therapeutic use, or a strain engineered after the disclosure - each of which needs a proper novelty search and a patent attorney's opinion.

Inventorship is a legal question about who contributed to the conception of the claimed invention; it has nothing to do with seniority, funding or lab headship. Here, the student who designed the screen, isolated the clone and recognised its activity is almost certainly an inventor. The PI is an inventor if she contributed to the conception of the claimed subject matter (for example the specific selection and characterisation strategy), not merely because she supervised or annotated the sequence. The foreign collaborator is an inventor only if he contributed to the conception of what is claimed; supplying a standard expression vector and performing a synthesis at others' direction is routine technical contribution and normally does not qualify. An incorrect inventorship declaration is a ground for revocation, so this must be analysed claim by claim and documented.

Ownership is a separate question governed by contracts: the university's IP policy, the student's enrolment or IP assignment terms (students are often not treated like employees in Indian universities, which is a live issue here), the employment terms of the PI, the sponsor's agreement, and the MTA.

Expected disputes:

• The university versus the student over whether her contribution was made in the course of her studies and whether she has assigned her rights.
• The university versus the foreign collaborator's institution over the vector-derived materials and any improvement made using them.
• The startup versus the university over scope of the sponsored research agreement and background IP.
• The Forest Department and the biodiversity authorities versus everyone, because none of the above can cure a breach of the permit or the absence of NBA approval. Resolve these through an invention disclosure, a written inventorship analysis and assignment/benefit-sharing agreements before any filing.

Answering the NGO: sovereignty over biological resources rests with the State, not with the university and not, in law, with the village as property; but the Biological Diversity Act creates a specific role for local communities through Biodiversity Management Committees, people's biodiversity registers and benefit sharing, and traditional knowledge associated with a resource is protected separately. So the honest answer is: the soil is not the university's to commercialise at will, the village has recognised consultative and benefit-sharing standing, and no benefit-sharing claim can be assessed without first checking whether any local or traditional knowledge of the organism exists and recording it. The NGO should be answered in writing and the Biodiversity Management Committee consulted.

Compliant path:

1. Pause the patent filing and the sponsored research agreement; put nothing on the strain beyond the existing preprint.
2. Obtain written permission from the Chief Wildlife Warden, renegotiating the permit terms if commercial work is to proceed.
3. Approach the State Biodiversity Board and file the NBA application for commercial utilisation and for transfer of results to a foreign collaborator, with a proposed benefit-sharing package (upfront payment, royalty, local capacity building, access to the derived product on reasonable terms).
4. Sign a proper MTA with the collaborator covering materials, results and IP, and reconcile the university's IP policy with the student's contribution.
5. Deposit the strain in a recognised culture collection under the agreed terms, and keep a documented chain of custody from the 40 soil samples to the clone.
6. Publish the compliance record alongside any future paper, and accept that the peptide itself may no longer be patentable - a defensive publication with an open licence, plus protection of an improved analogue or process, may be the realistic outcome.